Streetbeat News

Stock Prices

CMG

34 analysts have shared their evaluations of Chipotle Mexican Grill (NYSE:CMG) over the past three months, showing a mix of bullish and bearish perspectives. The average 12-month price target has decreased significantly, indicating a shift in sentiment. Despite this, Chipotle's financial health remains strong with impressive revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 1:00 pm

KZR

Kezar Life Sciences shares have resumed trading after a temporary halt. This development is significant for investors monitoring the company's stock activity.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:00 pm

BRKR

In the past three months, four analysts have rated Bruker (NASDAQ:BRKR) with mixed sentiments ranging from bullish to bearish. The average 12-month price target has decreased by 9.75% to $72.5. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Bruker has shown strong financial performance with a 17.42% revenue growth rate, but its debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 1:00 pm

LXEH

Trading for LXEH was halted and then resumed, with updates provided at 8:55 AM ET. This indicates a temporary pause in trading, possibly due to pending news or volatility.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:55 pm

ABBV

ACN

DIS

META

On CNBC's 'Final Trades', analysts discussed Meta, Accenture, AbbVie, and Disney. Meta received a price target increase, Accenture reported strong earnings, AbbVie shared positive trial results, and Disney is expected to see higher streaming profitability despite layoffs.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 12:43 pm

CBNA

Chain Bridge Bancorp has announced its initial public offering (IPO) of 1.85 million shares, with an expected price range of $24 to $26 per share.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:38 pm

KZR

Kezar Life Sciences has voluntarily stopped enrollment and dosing in its Phase 2b PALIZADE trial of Zetomipzomib for active lupus nephritis patients. This decision could impact the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:35 pm

NBIX

Neurocrine Biosciences presented interim data showing significant and sustained improvements in chorea associated with Huntington's Disease through week 104, regardless of antipsychotic use.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm

ASND

Ascendis Pharma presented 3-year data at ASBMR 2024, demonstrating that long-term treatment with TransCon PTH normalizes bone remodeling in adults with hypoparathyroidism.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm

ALCE

VVPR

The article highlights two oversold utility stocks, VivoPower International (VVPR) and Alternus Clean Energy (ALCE), which present potential buying opportunities. Both companies have experienced significant stock price declines and have RSI values indicating oversold conditions.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 12:32 pm